Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Court stings AbbVie with an AndroGel fine

Executive Summary

A US district court has ordered AbbVie and partner Besins Healthcare to repay consumers US$448 million, plus interest, for using ‘sham litigation’ to unlawfully delay generic competition to AbbVie’s AndroGel (testosterone) 1% gel brand, in the largest monetary award ever in a litigated US Federal Trade Commission (FTC) antitrust case.

You may also be interested in...



FTC Claims Revived Over Teva-AbbVie 'Pay For Delay' Deal

AbbVie and FTC both see wins and setbacks in Third Circuit ruling on case involving reverse-payment patent settlement with Teva.

Teva Leapfrogs Taro With Authorized Generic Epiduo Forte Launch

Teva has added another major dermatology brand to its armory, with the launch of an authorized generic version of Galderma’s Epiduo Forte Gel.

Amgen: We Expect To Double Biosimilar Sales By 2030

Amgen management paid close attention to the company’s biosimilar portfolio and pipeline during several recent calls with investors, including what differentiates the firm from its rivals in the biosimilars space.

Topics

UsernamePublicRestriction

Register

GB000977

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel